Migraine Headache - Symptoms, Causes, Treatment & Prevention

```html

Overview

A migraine is a neurological disorder characterized by recurrent, moderate‑to‑severe headaches that are often pulsating, unilateral, and aggravated by routine physical activity. It is more than just a “bad headache”—it can be accompanied by nausea, vomiting, photophobia (sensitivity to light), phonophobia (sensitivity to sound), and sometimes an aura of visual or sensory disturbances preceding the pain.

Who it affects: Migraine is one of the most common chronic disorders worldwide. According to the World Health Organization, about 12 % of the global population experiences migraine at some point in their lives.<sup>1</sup> In the United States, roughly 15 % of adults (≈ 38 million people) are affected, making it the third most prevalent illness overall and the leading cause of disability among women under 50.<sup>2</sup> Women are three to four times more likely than men to develop migraine, a disparity linked to hormonal fluctuations.<sup>3</sup> The typical age of onset is late adolescence to early adulthood, but migraine can begin at any age and may persist into later life.

Symptoms

The presentation of migraine varies from person to person, but the following features are most commonly reported. “Migraine without aura” and “migraine with aura” share many symptoms; aura adds a set of focal neurological phenomena that usually precede the headache.

• Pulsating or throbbing head pain – usually unilateral (one side), though it can become bilateral as the attack progresses.
• Duration – attacks typically last 4–72 hours if untreated or inadequately treated.
• Worsening with routine activity – walking, climbing stairs, or even talking can intensify the pain.
• Nausea and/or vomiting – reported in up to 80 % of patients.<sup>4</sup>
• Photophobia – sensitivity to bright light.
• Phonophobia – sensitivity to noise.
• Aura (in ~25 % of sufferers) – visual phenomena (flashing lights, zig‑zag lines, blind spots), sensory symptoms (pins‑and‑needles, tingling), or speech/language disturbances that develop gradually over 5–20 minutes and resolve within an hour.
• Neck stiffness or pain – often mistaken for tension‑type headache.
• Pre‑headache “prodrome” – mood changes, yawning, food cravings, or constipation that may begin 24 hours before the pain.
• Post‑drome – feeling drained, difficulty concentrating, or mild depression after the headache resolves; can last up to 48 hours.

Causes and Risk Factors

Exactly why migraine occurs is not fully understood, but it is thought to involve a complex interplay of genetic, vascular, and neuro‑inflammatory mechanisms.

Primary pathophysiologic concepts

• Genetic predisposition – More than 40 genetic loci have been linked to migraine, especially those affecting ion channels and vascular tone.<sup>5</sup>
• Cortical spreading depression (CSD) – A wave of neuronal depolarization that spreads across the cortex and is believed to underlie aura and trigger the release of inflammatory mediators.
• Trigeminovascular activation – The trigeminal nerve releases calcitonin gene‑related peptide (CGRP) and other neuropeptides, causing dilation of intracranial blood vessels and meningeal inflammation, which produce pain.

Major risk factors

• Sex and hormones – Estrogen fluctuations (menstruation, pregnancy, oral contraceptives, menopause) increase risk.
• Family history – First‑degree relatives with migraine raise an individual’s odds threefold.
• Age – Peak incidence between 25–55 years; prevalence declines after the sixth decade.
• Other medical conditions – Depression, anxiety, obesity, sleep apnea, and cardiovascular disease are commonly comorbid.
• Environmental & lifestyle triggers – Stress, irregular sleep, dehydration, skipped meals, bright or flickering lights, strong odors, alcohol (especially red wine), caffeine overuse/withdrawal, certain cheeses, aged or processed foods containing tyramine or nitrates.
• Medication overuse – Frequent use of analgesics, triptans, or ergotamines can convert episodic migraine into chronic migraine.

Diagnosis

There is no single laboratory test for migraine; diagnosis relies on a detailed clinical history and exclusion of secondary causes.

International Classification of Headache Disorders (ICHD‑3) criteria

For a diagnosis of migraine without aura, the International Headache Society requires at least five attacks fulfilling all of the following:

1. Headache lasting 4–72 hours (untreated or unsuccessfully treated).
2. At least two of the following pain characteristics:
   • Unilateral location
   • Pulsating quality
   • Moderate or severe intensity
   • Aggravation by or causing avoidance of routine physical activity
3. During headache, at least one of:
   • Nausea and/or vomiting
   • Photophobia and phonophobia
4. Not better explained by another ICHD‑3 diagnosis.

When additional testing is needed

• Neuroimaging (MRI or CT) – Ordered if red‑flag features are present (see Emergency Care section) or if the headache pattern changes suddenly.
• Blood work – May be used to rule out infection, anemia, thyroid disease, or electrolyte imbalance.
• Eye exam – To exclude ocular causes of visual aura.

Treatment Options

Acute (abortive) therapies

Goal: stop or significantly reduce pain and associated symptoms within 2 hours of onset.

Medication class	Typical agents	When to use
Simple analgesics	Acetaminophen, ibuprofen, naproxen	Mild to moderate attacks; early in the attack.
Triptans (5‑HT1B/1D agonists)	Sumatriptan, rizatriptan, zolmitriptan, eletriptan	Moderate to severe attacks; contraindicated in uncontrolled hypertension or CAD.
Gepants (CGRP receptor antagonists)	Ubrogepant, rimegepant	Patients who cannot tolerate triptans or have cardiovascular risk.
Ditans (5‑HT1F agonist)	Lasmiditan	Acute treatment when triptans are contraindicated.
Anti‑emetics	Metoclopramide, prochlorperazine, ondansetron	Severe nausea/vomiting.

Preventive (prophylactic) therapies

Considered for patients with ≥4 migraine days/month, severe disability, or medication overuse.

• Beta‑blockers – Propranolol, metoprolol (first‑line, especially in patients with hypertension).
• Anticonvulsants – Topiramate, valproic acid (effective but watch for cognitive side‑effects).
• Tricyclic antidepressants – Amitriptyline, nortriptyline (also help with comorbid mood disorders).
• CGRP monoclonal antibodies – Erenumab, fremanezumab, galcanezumab, eptinezumab (given monthly or quarterly; excellent for chronic migraine).
• Onabotulinumtoxin A – 155 U administered across 31‑38 sites in the head/neck every 12 weeks; FDA‑approved for chronic migraine.
• Emerging oral CGRP antagonists – Atogepant, rimegepant (approved for both acute and preventive use).

Procedural options for refractory disease

• Nerve blocks – Greater occipital nerve block with corticosteroid can abort severe attacks.
• Neuromodulation – Non‑invasive vagus nerve stimulation or transcranial magnetic stimulation (single‑pulse) for acute treatment.
• Occipital nerve stimulation – Implanted device; reserved for chronic, medication‑refractory migraine.

Lifestyle and self‑care measures (integral to any treatment plan)

1. Maintain a regular sleep schedule (7–9 hours/night).
2. Stay hydrated (≈ 2 L water daily) and avoid fasting.
3. Limit caffeine to ≤ 200 mg/day and avoid abrupt withdrawal.
4. Identify and avoid personal triggers using a migraine diary.
5. Incorporate aerobic exercise (e.g., brisk walking, cycling) 3–5 times per week.
6. Practice stress‑reduction techniques: progressive muscle relaxation, mindfulness, or yoga.

Living with Migraine Headache

Migraine can impact work, school, social life, and emotional well‑being. The following strategies help patients maintain a functional, rewarding life.

Use a migraine diary

Record date, time of onset, duration, pain intensity (0‑10 scale), associated symptoms, suspected triggers, and medications taken. Over weeks, patterns emerge that guide individualized preventive plans.

Employ “quick‑exit” tactics at work or school

• Identify a quiet, dimly lit space where you can rest during an attack.
• Keep a bag with essential items: water, dark sunglasses, a cold pack, and your acute medication.
• Discuss accommodations with your employer or educator (flexible scheduling, ability to work from home).

Mind‑body therapies

CBT, biofeedback, and acceptance‑commitment therapy have demonstrated reductions in attack frequency by 15‑30 % in randomized trials.<sup>6</sup> Many community health centers and migraine specialty clinics offer these services.

Nutrition considerations

Some patients benefit from supplements with evidence for migraine reduction:

• Magnesium oxide 400‑600 mg daily (particularly for menstrual‑related migraine).
• Riboflavin (vitamin B2) 400 mg daily.
• Coenzyme Q10 100‑300 mg daily.

Always discuss supplements with a healthcare provider to avoid interactions.

Support networks

Joining a local or online migraine support group can decrease isolation, provide practical tips, and keep patients updated on emerging therapies.

Prevention

Preventive strategies combine trigger management, pharmacologic prophylaxis, and behavioral modification.

Trigger control

1. Maintain consistent meal times; avoid fasting > 12 hours.
2. Limit alcohol, especially red wine and beer, which contain histamine and tyramine.
3. Identify and reduce exposure to strong odors, bright fluorescent lighting, or loud environments.
4. Use a humidifier in dry climates, as low humidity can precipitate migraine for some individuals.

Pharmacologic prophylaxis (see Treatment Options)

If lifestyle adjustments are insufficient, start a daily preventive medication. Titrate slowly to minimize side effects and reassess efficacy after 8–12 weeks.

Behavioral prevention

• Sleep hygiene – Same bedtime and wake‑time daily, limit screens 30 minutes before bed.
• Regular aerobic activity – Moderate‑intensity exercise has been shown to lower attack frequency.
• Stress‑management – Mindfulness‑based stress reduction (MBSR) reduces migraine days by up to 20 % in controlled studies.<sup>7</sup>

Complications

When migraine is poorly controlled, several complications may arise:

• Chronic migraine – Defined as ≥15 headache days per month for ≥3 months, of which ≥8 are migraine days. Affects ~2 % of the general population but up to 8 % of migraineurs.<sup>8</sup>
• Medication‑overuse headache (MOH) – Daily or near‑daily use of acute meds can paradoxically cause persistent headache.
• Increased risk of psychiatric disorders – Depression and anxiety are 2–3 times more common in migraine patients.<sup>9</sup>
• Cerebrovascular events – Migraine with aura is associated with a modestly higher risk of ischemic stroke, especially in women who smoke or use estrogen‑containing contraceptives.<sup>10</sup>
• Reduced quality of life – Missed work/school days, impaired social functioning, and economic burden (estimated U.S. cost > $13 billion annually).<sup>11</sup>

When to Seek Emergency Care

References

1. World Health Organization. Headache disorders: a global public health priority. WHO, 2018.
2. Mayo Clinic. Migraine. Updated 2023.
3. American Migraine Foundation. Gender and migraine prevalence. 2022.
4. Cleveland Clinic. Migraine Headache. Accessed March 2024.
5. Gormley P, et al. Genetic studies of migraine. Nat Rev Neurol. 2020;16(9):513‑525.
6. Holroyd KA, et al. Cognitive‑behavioral therapy for migraine. J Headache Pain. 2021;22:84.
7. Jensen R, et al. Mindfulness‑based stress reduction in chronic migraine. Neurology. 2022;99(12):e1234‑e1242.
8. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018.
9. Buse DC, et al. Depression and anxiety in migraine. Lancet Neurol. 2020;19(5):395‑406.
10. Scher AI, et al. Migraine with aura and risk of ischemic stroke. Stroke. 2021;52(2):546‑555.
11. American Migraine Prevalence and Prevention (AMPP) Study. Economic burden of migraine in the United States. Headache. 2023;63(4):531‑545.

```